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The pathogenesis of multiple sclerosis (MS) remains elusive. Recent reports advocate greater involvement of B cells and
immunoglobulins in the initiation and propagation of MS lesions at diﬀerent stages of their ontogeny. The key role of B cells and
immunoglobulins in pathogenesis was initially identiﬁed by studies in which patients whose fulminant attacks of demyelination
did not respond to steroids experienced remarkable functional improvement following plasma exchange. The positive response
to Rituximab in Phase II clinical trials of relapsing-remitting MS conﬁrms the role of B cells. The critical question is how B cells
contribute to MS. In this paper, we discuss both the deleterious and the beneﬁcial roles of B cells and immunoglobulins in MS
lesions. We provide alternative hypotheses to explain both damaging and protective antibody responses.
1.Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory demyeli-
nating disease of the central nervous system (CNS) with
varied clinical presentations and heterogeneous histopatho-
logical features. According to the National MS Society, ap-
proximately 400,000 people have been diagnosed with MS
in the United States, with approximately 200 new cases
every week. The main pathologic hallmark of MS is the de-
myelinated plaque, which has speciﬁc histological and im-
munocytological characteristics depending on the activity of
the disease [1–4]. Another important immunopathological
feature of MS is continuous synthesis of immunoglobu-
lins (oligoclonal IgG’s) in cerebrospinal ﬂuid (CSF). The
evidence associating antibodies with MS derives from a
study by Kabat et al., who ﬁrst described increased levels
of immunoglobulin (Ig) in the cerebrospinal ﬂuid (CSF)
[5]. For many years, self-reactive antibodies have been as-
sociated with the pathogenesis of MS, and their presence
was usually linked to demyelination based on studies done
in experimental autoimmune encephalomyelitis (EAE), the
most commonly studied model of MS [6].
EAE is induced in animals by intradermal injection
with whole or parts of various proteins that make up
myelin. It is primordial to understand that EAE is not MS;
it only resembles some forms and stages of MS. Hence,
a number of signiﬁcant assumptions made when proposing
EAE as MS may only be partially true. Evidence from
EAE studies favoring the role of antibodies in demyelina-
tion derived from three studies, (i) serum from animals
with EAE produced periventricular demyelinating lesions
when injected directly into the ventricles of normal animals,
[7, 8], (ii) gamma-globulin was deposited in the CNS
before the appearance of cells [9]; and (iii) serum from
animals with EAE produced by sensitization with whole
CNS-induced demyelination of CNS tissue cultures [10].
A feature that distinguishes species is the structural and
functional heterogeneity of antibodies in higher species2 Neurology Research International
such as mammals. EAE is commonly studied in rodents
and is mostly dependent on cellular immune responses
even if antibodies worsen the disease, with the exception
of models where pathogenic Th2 responses play a pivotal
role. The reader should understand that the heterogeneity
of antibody response and the diversity in their pathogenicity
was mostly suggested and best studied in primate models
of EAE [11] that closely reﬂect adequate complexity found
in humans. Two other animal models of MS are virus-
induced or toxin-induced demyelination [6]. Using a mouse
modelofTheiler’svirus-induceddemyelination,ourresearch
group showed that immunoglobulins and complement are
involved in the pathogenesis of demyelination [12]. In a
later study, in humans, we reported on four diﬀerent path-
ologic subtypes of active MS lesions among 83 biopsies and
autopsies of MS patients [1]. One of the subtypes, Type
II, demonstrated a prominent presence of antibodies and
complement. Antibodies directed against self-antigens are
frequently considered deleterious and may play a pathogenic
role in certain autoimmune diseases. A conventional method
to remove circulating autoantibodies in patients is termed
plasma exchange (PLEX). PLEX is a procedure that involves
separatingthebloodfromplasmaandexchangingtheplasma
with albumin and returning the cellular components back to
the patient. The large molecular weight substances that are
removed from plasma following PLEX remain a question of
open debate although it is certain that immunoglobulins and
immune complexesareamajorcomponent ofthe substances
that are removed. Few studies described evidence that PLEX
does more than just remove antibodies; PLEX (i) can alter
immune system by aﬀecting T helper type-1/T helper type-II
balance of circulating peripheral lymphocytes [13], (ii) can
shift Th2-dominant status to Th1-dominant status [14], (iii)
can decrease cytokine levels [15] ,a n d( i v )c a ni m p r o v ec e l l
function when administered along with prednisone [16].
2. Effect of Plasma Exchangein Patients with
DemyelinatingDisorders
Our group demonstrated conclusively for the ﬁrst time the
detrimental eﬀect of plasma components in inﬂammatory
demyelinatingdiseasesoftheCNS;PLEXinacuteepisodesof
fulminant CNS inﬂammatory demyelination, which did not
respond to high-dose methylprednisolone, led to a marked
neurologic improvement in 6 patients [18]. These results
were later conﬁrmed in a double-blind placebo-controlled
(sham procedure) trial performed at the Mayo Clinic,
which demonstrated that approximately 40% of patients
with acute, severe neurological deﬁcits caused by MS or
other CNS inﬂammatory demyelinating diseases who failed
to recover after treatment with high-dose corticosteroids
have dramatic recovery following PLEX [19]. In other
well-designed, controlled studies, the beneﬁcial eﬀect of
PLEX was demonstrated in patients with MS [20–22]. A
more recent study [23] from our group performed in 153
patients with acute, steroid-refractory CNS inﬂammatory
demyelinating disease (CNS-IDD) demonstrated moderate
to marked functional neurological improvement in 59% of
the cases within 6 months following PLEX. However, PLEX
waslesseﬀectiveforpatientswithmultiplesclerosiswhosub-
sequently developed a progressive disease course (P = .046).
Accordingly, a recently published evidence-based guideline
update concluded that PLEX is (i) probably effective and
should be considered as a second-line treatment of steroid-
resistantexacerbationsinrelapsingformsofMS,(ii)possibly
eﬀectiveandmaybeconsideredforacutefulminantdemyeli-
nating CNS disease, and (iii) is ineﬀective and should not
be considered for chronic or secondary progressive MS [24].
Treatment in relapsing-remitting MS includes azathioprine,
intravenous immunoglobulin (IVIg), interferon β-1a, glati-
ramer acetate, mitoxantrone hydrochloride, natalizumab,
and cyclophosphamide, depending on the disease severity.
A randomized, double-blinded, placebo-controlled trial of
IVIginpatientswithMSwhohadpersistentmuscleweakness
concluded that IVIg does not reverse established weakness
in MS [25]. PLEX has not been speciﬁcally studied in
relapsing-remitting MS. A traditional hampering factor
remains to be the excessive cost burden on the patient to
undergo PLEX procedure. Nevertheless, a recent estimate
established that a direct cost of ﬁve IVIg infusion sessions
totaling 2.0 grams per kilogram (g/kg) body weight was
$10,329.85 compared to a series of ﬁve TPE procedures,
which had direct costs of $4,638.16 [26]. Taking this into
consideration, further studies to understand the beneﬁcial
eﬀectsofPLEXarewarrantedgiventhattheoptimalprotocol
and the duration of beneﬁt remains un-established.
3. The Presenceof B Cellsin CNS
An MS plaque is histologically characterized by inﬂamma-
tion, demyelination, and gliosis. Inﬁltration by mononuclear
cells, particularly macrophages and T cells, is typical of
the acute MS lesion. Esiri showed that autopsy material
from the brains and spinal cords of 23 MS patients showed
that Ig-containing cells were more numerous within the
plaques than outside and were more common in recent
than in old plaques [27]. Subsequently, Cepok et al. showed
that B cells account for up to 25% of the CSF-inﬁltrating
leukocytes during CNS inﬂammatory responses [28]. To
better understand the potential mechanism of B cells in MS
pathology, Baranzini et al. had PCR ampliﬁed and analyzed
by size, spectratyping, and sequencing the Ig heavy chain
CDR3repertoirein10MSbrainsamples.Theirworkshowed
a higher level of rearranged transcripts in MS brains when
compared to the noninﬂammatory brain tissues, suggesting
that oligoclonal bands found by spectratyping are the result
of antibody synthesis within the plaques [29]. The above
ﬁndings supported the hypothesis that a germinal center-
(GC-) like reaction takes place during the immune attack
against CNS structures. This concept was further strength-
ened by Colombo et al. [30] who detected oligoclonal B cell
accumulations in 10 of 10 MS patients. Upon analyses of the
Ig V(D)J sequences from the CSF of patients, it was found
that variable heavy chain domains, VH3a n dV H4 genes, were
extensively mutated as compared to the germline sequences.
Their data suggested a compartmentalized clonal expansionNeurology Research International 3
in MS. This, however, raised the question on the capability
of the brain tissue to host a GC-like reaction. The works
of Knopf et al. provided the answers: they used a rodent
model with an intact blood-brain barrier and demonstrated
the traﬃcking of activated antigen-speciﬁc B cells into
the brain, retention, and antibody production [31]. Their
data proved that the brain microenvironment supports the
development of antigen-directed humoral immunity. To
conﬁrm this concept, Corcione et al., showed that each B-
cell subset participating in the GC reaction could be detected
in the CSF of MS patients [32].
4. Autoimmune Hypothesis and the Presence of
ImmunoglobulinsinCNS
AutoimmunityisthemostacceptedtheoryforMSpathogen-
esis, as self-reactive antibodies have been implicated in the
pathogenesis of MS. Previous studies suggested intrathecal
production of antibodies occurred after clonal expansion in
patients as seen by the consistent identiﬁcation of oligo-
clonal bands after CSF electrophoresis [33]. We reported
on the heterogeneity of MS lesions in CNS tissue and
their implications for the pathogenesis of demyelination. We
performed a detailed immunohistochemical study of active
MS lesions from 83 biopsies and autopsies of MS patients,
following which we identiﬁed four diﬀerent pathologic
subtypes of active MS lesions. One of the subtypes, Type
II, demonstrated the presence of macrophages and T-cells
and, in addition, a prominent display of antibodies and
complement [1]. Numerous publications during the last
few decades supported the idea that CSF oligoclonal bands
correlate to the level of B-cell involvement in MS [34]. In
addition, evidence indicates that oligoclonal bands may have
a prognostic value. One prospective study of patients with
acute isolated demyelinating episode demonstrated intrathe-
cal immunoglobulin synthesis to be a better predictor of
MS progression than MRI [35]. Another prospective study
showed that the presence of CSF oligoclonal bands in early
MS generally correlated to a worse outcome [36]. A recent
studyshowedstrongcorrelationbetweenlevelsofoligoclonal
bands (OCBs) and prognosis for MS disability [37].
Our work [1, 18, 19] and others’ results [38, 39]f a v o r
antibody-mediated demyelination in MS. On the contrary,
in a recent study comparing the immunoglobulins and ac-
tivated complement in MS and other neurologic diseases
(ONDs) patients, the authors did not ﬁnd IgG in myelin
or ramiﬁed microglia from tissue remote to focal lesions
[40]. Interestingly, C3d and C9neo stained positively for all
IgG from MS and ONDs. The only MS-speciﬁc IgG depo-
sition they found consisted of unusual microglial nodules
containing short, linear deposits of activated complement
(C3d) on partially demyelinated axons located in normal-
appearing periplaque white matter. This study thus argued
that the IgG and complement immunostaining of disrupted
myelin in MS lesions is a nonspeciﬁc feature that cannot be
interpreted as evidence of a distinct pathogenesis or serve
to deﬁne particular variants of the disease. However, it is
questionable whether many of the lesions in the study were
as acute as those in the studies performed at Mayo [1].
In the past, Avrameas proposed that autoreactive anti-
bodies present in healthy humans have natural physiological
roles [41]. In line with this, we have shown that im-
munoglobulins directed against antigens of the lipid rafts of
oligodendrocytes promote remyelination in CNS. Systemic
injection of serum molecules from donor mice hyperim-
munized with homogenized spinal cord induced the re-
myelination of CNS axons. This was the ﬁrst evidence
that immunoglobulins secreted in demyelinating lesions
may have the potential to promote myelin repair [42]. We
have further demonstrated that human immunoglobulins,
when used to treat animal models of disease, can promote
remyelination [43] and neurite extension [44]. Protecting
axons of the CNS promises to be an eﬀective strategy to
limit axon loss and prevent permanent disability. Thus, there
is a delicate balance between the presence of beneﬁcial and
deleterious immunoglobulins at the site of active lesion.
5. Antigen Speciﬁcityof Autoantibodies
Found in MS
After several years of research, conﬁrmation of the antigen-
speciﬁcity of autoreactive antibodies in MS is still lacking.
Due to their broad reactivity, IgG in CSF of patients with MS
may represent synthesis of “nonsense” antibodies irrelevant
to pathogenesis [45–47]. However, other experiments found
molecular uniformity and temporal persistence of the Ig
response in MS, thus conﬂicting with the nonsense antibody
proposal [48]. It is possible that relevant molecules are lim-
ited to the myelin sheath. Warren and Catz studied the speci-
ﬁcities of autoantibodies from MS patients and reported that
most patients’ IgG bound to MBP. They also reported that
the peptide MBP [49–63] strongly inhibited autoantibody
binding to MBP in almost all cases tested [64]. Genain et al.
oﬀered the most convincing ev idence. Using immunogold-
labeled peptides of myelin antigens and high-resolution
microscopy (techniques that can detect antigen-speciﬁc
antibodies in situ), they identiﬁed autoantibodies speciﬁc
for the CNS myelin antigen myelin/oligodendrocyte glyco-
protein (MOG). These autoantibodies speciﬁcally bound to
disintegrating myelin around axons in acute MS lesions and
the marmoset model of EAE [65]. O’Connor et al. examined
whetherautoantibodies thatbindproperly foldedMOGpro-
teinarepresentintheCNSparenchymaofMSpatients.Their
data demonstrated that MOG-recognizing autoantibodies
are present in substantially higher concentrations in the CNS
parenchyma of MS patients than in the CSF and serum. This
indicated that local production/accumulation is an impor-
tant aspect of autoantibody-mediated pathology in CNS
demyelinating diseases [66]. Further studies demonstrated
the serological and/or CSF presence of antibodies directed
against MBP and/or MOG in patients with MS [67].
Conversely, myelin-speciﬁc antibodies are not limited
to MS. Using an enzyme-linked immunosorbent assay,
Karni et al. compared levels and frequencies of anti-MOG
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and healthy control subjects. Interestingly, the authors found
higher plasma levels of antibodies to MOG and to MBP in
MS patients compared with ONDs patients; however, the
frequencyofantibodiestoMOGandMBPwassimilarinMS,
ONDs and healthy controls [68]. Another group presented
analogous results. Lampasona et al. used a liquid-phase
radiobinding assay to measure serum anti-MOG IgG among
87 MS patients with MS, 12 encephalomyelitis patients and
47 healthy subjects. Surprisingly, the frequency of positive
samples with low titers of anti-MOG IgG was similar in
all the groups and subgroups. Binding-competition exper-
iments showed that low aﬃnity in these antibodies. These
results demonstrated that anti-MOG antibodies are not
disease speciﬁc [69].
In a parallel line of research, some reports suggested
lipids or carbohydrates as possible candidate antigens for the
humoral immune response. Arnon et al. reported the pres-
ence of anti-ganglioside antibodies in MS [70]. Endo et
al. reported the presence of antibodies to glycosphin-
golipids in MS patients [71]. Their results indicated that
antibodies against ganglioside GM1 and asialo GM1 were
found commonly in 34 of 46 patients with MS. However,
antilipid antibodies can be found in other diseases, such
as systemic lupus erythematosus and stroke [72, 73]. An
interesting report identiﬁed anti-alpha-glucose-based glycan
IgM antibodies as predictors of relapse activity in MS after
theﬁrstneurologicalevent[74].Otherssuggestedthatserum
anti-Glc(alpha1,4)Glc(alpha)antibodiesserveasbiomarkers
for relapsing—remitting MS [75]. Villar et al. reported
that the intrathecal synthesis of oligoclonal IgM against
myelin lipids may predict an aggressive disease course in MS
[76]. The most frequently recognized lipid in their study
was phosphatidylcholine. Autoantibodies to myelin proteins,
lipidsandcarbohydratescanbeextractedfromthetissueand
sera of some MS patients.
A major discovery in demyelinating disorders was when
Hinson et al. [77–79] discovered a potential pathogenic im-
munoglobulin G binding to the extracellular domain
of a water channel aquaporin-4 (AQP4) in patients
with neuromyelitis optica (NMO). Potential pathogenic
immunoglobulins appear in approximately 70% of patients
with NMO. It is unknown whether a detection problem lim-
itstheassayintheremainingpatientsorifanautoantibodyto
ad i ﬀerent antigen drives the response. However, no clinical
diﬀerences exist between antibody-positive and antibody-
negative patients with clinical NMO. A randomized trial to
determine whether IVIg reverses chronic visual impairment
in MS patients with optic neuritis (ON) demonstrated that
IVIg administration does not reverse persistent visual loss
from ON to a degree that merits general use [80]. Interest-
ingly,PLEXisahighlysuccessfultreatmentforNMOarguing
in favor of an autoimmune-mediated pathogenesis of this
disease. In line with the autoimmune-mediated hypothesis,
humoral immunity-suppressing drugs such as Mitoxantrone
hydrochloride [81], (a synthetic anthracenedione that was
approved for the treatment of worsening relapsing-remitting
and secondary progressive MS), Mycophenolate Mofetil
[82], (an immunosuppressive therapy), and Rituximab [83],
(a B cell depleting therapy) were demonstrated to be ben-
eﬁcial for treatment of NMO.
It is now considered that NMO is likely the ﬁrst true
demyelinating autoimmune disorder. Autoantibodies may
contribute to the ongoing immune response, but after more
than 50 years of investigation in the ﬁeld, one still cannot
substantiate all the criteria necessary to classify MS as an
autoimmune disease [84]. In light of this, the autoimmune-
hypothesis requires a complementary hypothesis/reason for
pathogenesis of MS.
6.AlternateHypothesisof MSPathogenesis
MS is a complex and heterogeneous disease; hence, in addi-
tiontotheautoimmunehypothesis,itisassumedthatcertain
infectious agents play an important role in the pathogenesis.
Epstein-Barr virus (EBV), human herpes virus-6 (HHV-6),
varicella zoster virus (VZV), and Chlamydia pneumonia are
some of the proposed infectious agents. Many studies in this
area have demonstrated the presence of antibody titers to
a broad range of pathogens in MS patients; however, many
of these ﬁndings remain solitary and unconﬁrmed by other
groups. EBV is a B-lymphotropic human DNA herpes virus
that infects most individuals asymptomatically but causes
infectious mononucleosis (IM) in some [85, 86]. Cepok et
al. identiﬁed EBV proteins as putative targets of the immune
response in MS [87]. Another study demonstrated the
increased risk of MS in individuals with a clinical history of
IM [88, 89]. Recently, researchers from the United Kingdom
studied the prevalence of MS and infectious mononucleosis
(IM) and how they relate to ultraviolet B (UVB) exposure
[90]. As previously shown in other studies, MS highly
correlated with IM [91, 92]. As a control, the authors
also examined correlations of MS with cytomegalovirus
prevalence and varicella prevalence, respectively, both of
which were nonsigniﬁcant. Of note, the authors found that
UVB in any season correlated more closely with MS than
with IM. These results ﬁt well with the EBV hypothesis,
because there may be a mechanism through which UVB
radiation mediates MS risk.
It has been suggested that low vitamin D levels as a
result of immunosuppression lead to an increase in EBV
infection. It is also known that a low amount of UVB
decreases vitamin D levels. The geographical variation in the
MS prevalence, with a higher prevalence of the disease in
northern latitudes and a lower prevalence at the equator, is
well established [93–95]. This variation in MS prevalence
correlates positively with changes in the serum concentra-
tions of 25-hydroxyvitamin D [96–98]. Several, but not
all, studies show an inverse correlation between serum 25-
hydroxyvitamin D concentrations and the incidence of MS,
the severity and progression of disease [49–61]. Vitamin D,
and its biologically active metabolite 1,25-dihydroxyvitamin
D3(1,25(OH)2D3), not only plays an important role in
the regulation of calcium and phosphorus homeostasis,
but also is an important modulator of immune function.
1,25(OH)2D3 functions by associating with the vitamin
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calcium-transporting tissues, neural tissues, and immune
cells (dendritic cells, T-lymphocytes, B-lymphocytes, and
macrophages) [62, 63, 99–104]. 1,25(OH)2D3 increases
macrophage activity, inhibits dendritic cell maturation,
inhibits B-cell functions, and favors the production of T-
helper2 cells, thereby shifting the ratio of Th1/Th2 cells
in favor of Th2 helper cells (Figure 1)[ 17, 105–111]. The
polarization of activated CD4 + T-cells to a Th-1 phe-
notype (IL-2, IFNγ,T N F α a n ds e c r e t i o n )o rt oaT h -
2 phenotype (IL-4, 5, 13, and 10 secretion) represents a
major determinant of the nature of subsequent cellular
and humoral immune responses. It is a self-perpetuating
process in that one subtype inhibits the generation of the
other [108, 110]. The primary generation of Th-1-type T-
cell responses is potently inhibited by 1,25(OH)2D3 both
in vitro and in vivo. 1,25(OH)2D3 also induces production
of human cathelicidin, LL-37, which is particularly eﬀective
against respiratory viruses such as inﬂuenza [112]. The lack
of vitamin D may result in abnormal response to EBV
infection causing IM, thereby leading to a higher risk for MS
[113].
7. Role of B Cells
7.1. As Antigen-Presenting Cells. The role of B cells in acute
demyelination was discussed in the previous sections (accu-
mulation of clonally expanded B cells, neuropathological
studies, and presence of complement). Besides their role in
acute demyelination, B cells can contribute to the disease
progression in MS [114]. It was previously shown that
epitope speciﬁcities generated in a mouse model of MS, EAE,
overlap with encephalitogenic T cell epitopes, and human
immune-dominant T and B cell epitopes [115–117]. Harp et
al. studied the impact of myelin-speciﬁc antigen-presenting
B cells on T cell activation in MS. Their results demonstrated
apossibleroleofBcellsasmyelin-speciﬁcantigen-presenting
cells (B-APCs) in MS [118].
Another treatment strategy used is Rituximab, an anti-
CD20 monoclonal antibody. CD20 is a surface antigen with
restricted expression on pre-B and mature B cells, but it
is not expressed on stem cells and cells diﬀerentiating into
plasma cells. Recent reports showed some favorable results
of Rituximab in relapsing-remitting MS patients, as the
administrationofthisdrugreducedinﬂammatorybrainMRI
lesions and clinical relapses for 48 weeks in patients, after
a single dose course [119, 120] .As t u d yb yC r o s se ta l .
showed that Rituximab reduces B and T cells in CSF of
MS patients [121]. However, the rapid eﬀect of Rituximab
is not explained by the fact that it does not act on plasma
cells or cells diﬀerentiating into plasma cells. Rituximab may
target the processes such as antigen presentation by B cells
and activation of T cells. This may aﬀect the production
of proinﬂammatory and regulatory cytokines in the CNS
microenvironment. In line with this, a recent study in
MS patients on Rituximab demonstrated that the episodic
triggering of abnormal B-cell cytokine responses mediated
“bystander activation” of disease-relevant proinﬂammatory
T cells [122].
7.2. As Cytokine-Producing Cells. As described before, the
studyofBar-Oretal.proposedthatabnormalB-cellcytokine
responses were responsible for new MS relapses through
bystander activation of relevant proinﬂammatory T-cells
[122]. This ﬁnding was important and may explain the
established association between new MS relapses and infec-
tions. The importance of balanced proinﬂammatory and
anti-inﬂammatory B-cell cytokines was demonstrated when
selective deletion of IL-10 from B-cells aggravated clinical
disease in EAE [123]. In addition, a recent study showed
that IL-10 secretion by B-cells was deﬁcient in MS patients
as compared to healthy controls [124]. However, levels of
IL-10 production were equivalent in patients with relapsing-
remitting and secondary progressive MS.
8. Mechanisms of Action of MS Antibodies
Antibodies are the antigen-binding proteins present on the
B-cell membrane and are secreted by the plasma cells. Mem-
brane-bound antibody confers antigenic speciﬁcity on B
cells; antigen-speciﬁc proliferation of B-cell clones is elicited
by the interaction of membrane antibody with antigen. The
versatility of secreted antibodies is demonstrated by the
functions they mediate such as neutralization, agglutination,
ﬁxation with activation of complement, and activation of
eﬀector cells. Among the antibody functions is a novel prop-
erty of the antibodies that fascinated scientists for several
years.Itistheabilityofsomeantibodiestobehaveasenzymes
with catalytic ability. Catalytic immunoglobulins, both of
the IgM and IgG isotypes, have been detected in the serum
of healthy donors, where they presumably participate in
removing metabolic wastes and defend the organism against
invading pathogens. Conversely, antigen-speciﬁc hydrolytic
IgGs are seen in a number of inﬂammatory, autoimmune,
and neoplastic disorders; their pathogenic eﬀects have been
demonstrated occasionally. Studies during the past decades
have shown antibodies to be capable of participating in at
least one of the functions presented below.
8.1. Functions of Immunoglobulins
(1) Neutralization. The Fab region of the antibodies binds to
the target (viruses, microbes [125], and/or toxins [126]) and
blocksorneutralizestheiraction.Thereissomeevidencethat
antibodies present in plaques bind to MBP and/or MOG and
neutralize and cause deterioration of the tissue; however, the
resultsremaincontroversialduetothepresenceofantibodies
with similar speciﬁcities in healthy blood donors.
(2) Agglutination. Antibodies are clonally generated for
binding single speciﬁc antigens. The Fab regions of the
antibodies link the antigens together, causing them to
clump together, also known as agglutination [125]. Mon-
oclonal antibodies derived from MS patients’ agglutinated
liposomes made from lipids of a chloroform/methanol
extract of human myelin. Investigations by ELISA suggest
that phospholipids are the reactive components, at least
for some of these mAbs. Some antibodies reacted with6 Neurology Research International
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Figure 1: The in vitro eﬀects of 1,25(OH)2D on the immune system. The eﬀects of 1,25(OH)2D either directly or indirectly are depicted
by arrows. While a green arrow represents positive inﬂuence, a red arrow represents the negative inﬂuence. The negative inﬂuence on
inﬂammation indicates dampening of the inﬂammatory response. DC: dendritic cell, Th1: T helper type 1 lymphocyte, Th2: T helper type 2
lymphocyte, Tr: regulatory T lymphocyte [17].
liposomes containing galactocerebroside or sulfatide, others
only with sulfatide-containing liposomes. However, there is
no reported evidence for role of this binding for MS [127].
(3) Fixation and Activation of Complement. The antibodies
that bind to surface antigens on, for example, a macro-
molecular structure, will attract the ﬁrst component of
the complement cascade with their Fc region and initiate
the activation of the “classical” complement system [128].
This results in the destruction of the molecule [125].
We previously described complement deposition in MS
plaques [1]. Complement activation is known to occur in
white-matter MS lesions. Storch et al. described a case
of MS characterized by deposition of immunoglobulin
and complement in the areas of active demyelination. In
addition, macrophages in the lesions contained degradation
products that were immunoreactive for myelin antigens
and immunoglobulins. They observed that the destruction
of myelin sheaths was associated with incomplete loss of
oligodendrocytes in the active areas and reappearance of
oligodendrocytes with remyelination in the inactive plaque
center [129]. Finally, Piddlesden et al. showed that the
demyelinating potential of antibodies to MOG was related
to their ability to ﬁx complement [130].
(4) Activation of Eﬀector Cells. Mast cells and phagocytes
have Fc receptors that interact with the Fc region of IgA, IgG,
and IgE antibodies. The engagement of a particular antibody
with the Fc receptor on a particular cell triggers the eﬀector
function of that cell (e.g., phagocytes will phagocytose
and mast cells degranulate) that will ultimately result in
destruction of the invading microbe. One or more FcRs
are expressed in microglia, astrocytes, oligodendrocytes, and
neurons.AberrantactivationofFcRsinsuchneuralcellsmay
contribute to MS pathogenesis [131]. Antimyelin antibodies
maymediatedamagetomyelinmembranesthroughseparate
mechanisms such as receptor-mediated phagocytosis by
macrophages and/or presentation of myelin autoantigens
to speciﬁc T cells [65]. Autoantibodies may activate mast
cells and cause their degranulation. The concept of mast
c e l l si nM Sd a t e sb a c kt om o r et h a nac e n t u r y .N e u m a n n
in 1890 described the ﬁrst association of mast cells to MS
plaques [132]. Olsson identiﬁed mast cells in MS plaques,
in 1974 [133]. Kruger et al. suggested in 1990 that mast
cells contribute to the demyelinating process of MS [134]. A
deﬁnite role for mast cells was ﬁnally demonstrated using the
mast cell-deﬁcient mice. These mice exhibited delayed onset
and decreased EAE disease severity when compared to wild-
type littermates [135].
(5) Eﬀector Functions of Immunoglobulins. The Fc region
mediates eﬀector functions, such as antibody-dependent cel-
lularcytotoxicity(ADCC)andcomplement-dependentcyto-
toxicity (CDC). In ADCC, the Fc region of an antibody
binds to Fc receptors (FcγRs) on the surface of immune
eﬀector cells such as natural killers and macrophages,
leading to the phagocytosis or lysis of the targeted cells.
In CDC, antibodies kill the targeted cells by triggering the
complement cascade at the cell surface. Frick and Stickl
demonstrated that antibodies from sera of MS patients
enable normal lymphocytes to exhibit a cytotoxic reaction
against MBP [136, 137]. Later, Merrill et al. compared
the peripheral blood lymphocytes (PBL) of MS patients to
age- and gender-matched controls for ability to mediate
ADCC. They demonstrated an enhanced ADCC of blood
lymphocytes of MS patients [138].
(6) Catalytic Activity of Ig. In most of the above-described
functions of Ig, the antibodies tightly bind the antigen
but does not speciﬁcally alter its chemical nature. Natural
enzymes within the body bind biomolecules and subse-
quently catalyze their conversion to new products. Within
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active site determine speciﬁcity and the eﬃciency. Consid-
ering the huge variability of the CDR regions, it is possible
to ﬁnd similar amino acid sequences in the hypervariable
zone of the Igs, which could confer an enzymatic function to
the antibody. Indeed, antibodies that catalyze a wide variety
of reactions have been reported. The ﬁrst description of
catalytic antibodies to MBP was documented in SJL mice
with EAE [139]. Since then, hydrolytic anti-MBP antibodies
were isolated from MS patients [140]. Six preferential cleav-
age sites of the MBP molecule were identiﬁed by abzymes
isolated from patients with MS [140, 141]. All the identiﬁed
cleavage sites were located c-terminus to either arginine or
lysine residues, thus providing an insight into the possible
mechanism of action of abzymes (a serine protease-like
activity). Aprotinin, a binding inhibitor of trypsin, could
not block abzyme-mediated hydrolysis. The mechanism of
action of these abzymes in comparison to conventional
serine proteases would be of interest to protein biochemists
studying structure-function relationship of proteins.
(7) Remyelinating Antibodies. The discovery of the function
of natural autoantibodies for CNS remyelination by our
group was serendipitous. At the point of discovery, we were
trying to induce more demyelination in an animal model of
demyelinating disease (Theiler’s virus infection) to test the
hypothesis of virus-induced autoimmunity. However, when
we immunized animals with myelin months after Theiler’s
virus infection, as opposed to extensive demyelination [142],
we observed extensive remyelination [42]. As a result, we
performed a classical passive transfer experiment in which
we transferred antisera or puriﬁed immunoglobulins from
uninfected animals immunized with myelin antigens into
animals with extensive chronic demyelination following
Theiler’s infection [143, 144]. Of interest, the animals re-
ceiving hyperimmune sera or immunoglobulin directed
against myelin showed extensive remyelination in contrast
to animals that received the control antisera. Our research
group then identiﬁed 8 diﬀerent mouse mAbs that promoted
remyelination [145]. Of note, each mAb bound unique
antigens or to the surface of oligodendrocytes [146]. They
all had relatively conserved germ line sequences [147, 148].
Based on this observation, we asked whether natural autoan-
tibodies were present in the human population. We sought
patients with disease processes that cause them to make
theirownmAbs,speciﬁcallypatientswithmultiplemyeloma,
Waldenstrom’s syndrome and monoclonal gammopathy
of unknown signiﬁcance. The serum samples from these
patients were screened for binding to sliced live cerebellum
and, speciﬁcally, to oligodendrocytes in culture. Two mAbs
that we screened, sHIgM22 and sHIgM46, demonstrated
very extensive remyelination [43] in both Theiler’s virus
and in lysolecithin-induced demyelination [149]. We also
identiﬁed antibodies (sHIgM12 and sHIgM42) that support
neurite extension in vitro as well as in the potent substrate
laminin and override the neurite outgrowth inhibition of
CNS myelin [44]. sHIgM22 [150] and sHIgM12 [151]
are now available as recombinant IgM molecules. These
results provide strong evidence for a beneﬁcial response of
antibodies in demyelinating diseases.
9. Role of Immunoglobulins
9.1. Deleterious Role. B cells also produce myelin-speciﬁc
antibodies that bind to and destroy myelin within the plaque
through an enzymatic mechanism. In this respect, catalytic
antibodies have been reported to play a role in site-speciﬁc
myelin destruction [139, 140]. The hydrolytic activity of
the anti-MBP antibodies correlated with the expanded
disability status [152]. Belogurov et al. [39]r e p o r t e do n
the recognition and degradation of MBP peptides by serum
autoantibodies. The authors used a constructed MBP-
derived recombinant “epitope library” that spanned the
entire MBP molecule to deﬁne the epitope-binding/ cleaving
activities of autoantibodies isolated from the sera of 26
MS patients and 11 healthy individuals. The levels of au-
toantibodies to MBP fragments, as well as to whole MBP
and myelin oligodendrocyte glycoprotein (MOG) molecules,
were signiﬁcantly higher in the sera of MS patients than
in those of healthy donors. Patients with MS (77% of
progressive and 85% of relapsing-remitting) were positive
for catalysis, showing pronounced epitope speciﬁcity to the
encephalitogenic MBP peptide 81–103. No healthy donors
presented with these characteristics. Based on the results,
anti-MBP binding and cleavage by abzymes may be regarded
asaspeciﬁcfeatureofMSascomparedtohealthydonorsand
may provide an additional marker of disease progression.
9.2. Beneﬁcial Role. Our group reported on the identiﬁ-
cation of monoclonal IgM antibodies with remyelinating
(sHIgM22 and sHIgM46) and neuroprotective (sHIgM12
and sHIgM42) properties. We have demonstrated that
rHIgM22 binds to oligodendrocytes and myelin and pro-
motes CNS remyelination in virus- and toxin-induced mod-
els of MS. Spinal cord remyelination is induced after a single
low dose (25μg / m L )o fr H I g M 2 2[ 153]. It is remarkable that
one peripheral (i.p.) treatment with a short-lived molecule
(15hr half life in mice) promotes maximal tissue repair
within 5 weeks in a model of MS with little spontaneous
repair. The properties of rHIgM22 are similar to a targetable
growth factor. After peripheral injection, rHIgM22 crosses
the blood brain barrier (BBB) and accumulates within brain
and spinal cord lesions of mice with demyelination. Ferritin
bead-labeled rHIgM22 hasbeen detected in lesionsin vivo by
magneticresonanceimagingshowingthattheantibodies can
readily cross the BBB [154]. In addition, repair-promoting
antibodies induced distinct Ca2+ signals in both astrocytes
and oligodendrocytes. The antibody’s ability to induce Ca2+
signals is statistically correlated with promotion of myelin
repair [155]. In addition, we showed that rHIgM22 strongly
inhibits apoptotic signaling via reduction of caspase-3 and
caspase-9 cleavage and reduces expression of diﬀerentiation
markersMBPandMOGinoligodendrocytecultures.Wealso
documented that remyelination-promoting human IgMs
protect oligodendrocytes in culture from peroxide-induced
activation of caspase 3 [156] ,am a r k e ro fa c t i v ea p o p t o s i s .8 Neurology Research International
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Figure 2: The role of B cells in MS pathogenesis. Antigens (viral, processed, novel, or auto) are internalized and presented via antigen
presenting cells (APC’s, such as dendritic cells, microglia and other mononuclear phagocyte system cells) to antigen-speciﬁc na¨ ıve T cells
and/orBcells.BcellscansometimesactasAPC’s.ActivatedBcellsundergoclonalexpansionandmatureintoeitherantigen-speciﬁcmemory
B cells or into plasma cells that secrete antigen-speciﬁc antibodies that may have a detrimental (further damage to myelin sheaths of axons)
or a beneﬁcial eﬀect (remyelination, clearing the metabolic wastes away, and neurite extension), depending on the microenvironment. The
oligoclonal immune response observed in patients with MS thus represents an ambivalent role. It is of priority to determine clinical assays to
delineatepatientswhowouldrespondtoBcelldepletiontherapies, ortoremyelinationpromotingantibodytherapy.Thisapproachsupports
the concept of “individualized medicine”, where deleterious antibodies would be removed from circulation or in other cases endogenous
remyelination would be promoted.
Our group then identiﬁed Lyn kinase as a key player in
rHIgM22-mediated eﬀects in OLs. We isolated integrin
αvβ3a n dP D G F αR in a complex together with Lyn kinase,
suggesting that rHIgM22 acts through a signaling complex
containing Lyn, integrin αvβ3, and PDGFαR in oligodendro-
cytes. This implies that IgM-mediated remyelination is due
to protection of oligodendrocyte progenitor cells and oligo-
dendrocytes rather than promotion of OPC differentiation
[157].
10. Conclusions
Over the past decades, accumulated evidence emphasized
the role of immunoglobulins in MS. The antibodies are
characterized with both detrimental as well as beneﬁcial
roles. A number of fundamental questions related to im-
portant problems of immunoglobulins in MS still have
ambiguous answers. New experimental design strategies and
technologies will help answer these questions more precisely.
A pivotal question is why some immunoglobulins cause
deleterious eﬀects, whereas others are beneﬁcial. Is antigen
recognition a unique attribute that determines this role?
This seems unlikely given that myelin-speciﬁc antibodies are
reported from both MS patients and healthy controls [158].
We propose that their microenvironment determines
whether immunoglobulins assume a pathogenic or repar-
ative role. Antibodies play a deleterious role when bound
t om y e l i na n dr e s u l ti ni t sd e g r a d a t i o n[ 140]. Alternatively,
antimyelin antibodies clear myelin debris from sites of
acute degradation to promote remyelination [159]. Another
factor may be the intracellular events mediated in the
target cell upon binding. We have shown that polyclonal
Ig treatment strategies, such as IVIg or IVIgM, promote
CNS repair via Fc-mediated activation of microglia and
stimulation of IL-1β release. The interaction of Fcγ or Fcμ
with receptors on microglia may initiate a cascade of events
culminating in IL-1β-induced oligodendrocyte progenitor
maturation and subsequent remyelination of demyelinatedNeurology Research International 9
lesions[160].Theseobservationssupportthehypothesisthat
the oligoclonal immune response [27, 28, 32] found in the
CSF and CNS parenchyma of MS patients with MS may
representapowerfulendogenousrepairsystem.Theevidence
of antimyelin antibodies in healthy donors again supports
the idea that these responses are not pathogenic but may be
part of an endogenous repair system.
All approved treatments for MS have targeted T-cells.
Because of the clear role of B-cells in MS pathogenesis, there
is a need to develop strategies to target this cell type. Treat-
ment of MS patients with either B cell-depleting therapies,
such as the administration of Rituximab or PLEX, has had
very signiﬁcant positive eﬀects on a small percentage of the
MSpopulation.However,themajorityofpatientsshowmin-
imal response to these treatments. In light of these ﬁndings,
weconsideritimperativetodevelopinvitrolaboratoryassays
todistinguish,whichpatientsrespondtostrategiestodeplete
B cells or remove immunoglobulins. Similarly, it will be
critical to determine which patients respond to a human
monoclonal antibody to promote remyelination. The results
from these assays can be used to select or optimize patient’s
preventive or therapeutic care. This is especially important
for patients with progressive forms of MS or patients who
havenotrespondedtoanycurrentlyavailabletreatments.For
instance,PLEXcouldbeconsideredasaﬁrstlineoftreatment
for patients with injurious or deleterious immunoglob-
ulins. Conversely, in patients with axonal preservation,
an endogenous remyelination-enhancing approach may be
appropriate. Ultimately, this supports the concept of “indi-
vidualized medicine” (Figure 2). However, the paucity of
available data from serology, genomics, proteomics, and
metabolomics from large cohorts of MS patients remains a
major limitation.
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